Drug Profile
Maribavir - Takeda
Alternative Names: 1263W94; Benzimidavir; Camvia; GW 1263; GW 1263W94; LIVTENCITY; LIVTENCITYTM; Maribavir - Shire; SHP-620; TAK 620; VP41263Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Takeda; ViroPharma
- Class Antivirals; Benzimidazoles; Ribonucleosides; Small molecules
- Mechanism of Action Ganciclovir kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cytomegalovirus infections
Most Recent Events
- 26 Dec 2023 Registered for Cytomegalovirus infections in China (PO)
- 21 Dec 2023 Maribavir - Takeda receives Breakthrough Therapy status for Cytomegalovirus infections (Prevention) in China
- 30 Nov 2023 Preregistration for Cytomegalovirus infections (In adolescents, In the elderly, In adults) in Japan (PO) (Takeda pipeline; February 2024)